FIELD: chemistry.
SUBSTANCE: invention relates to biochemistry, in particular to a recombinant HER2 binding protein comprising at least first and second ankyrin repeat domains, each of which binds the extracellular region of HER2. First ankyrin repeat domain binds domain II of HER2, and second ankyrin repeat domain binds domain IV of HER2, the first and second ankyrin repeat domains are in the same polypeptide, the first ankyrin repeat domain is at the N-terminus of the second ankyrin repeat domain. Also disclosed is a nucleic acid encoding the aforementioned binding protein. Invention also relates to a pharmaceutical composition comprising the aforementioned binding protein, as well as a method for treating cancer characterised by amplification of the HER2 encoding gene and / or overexpression of the HER2 encoding gene using same.
EFFECT: invention can effectively treat cancer characterised by amplification of the HER2 coding gene and/or overexpression of the HER2 encoding gene.
32 cl, 7 dwg, 3 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECOMBINANT BINDING PROTEINS AND THEIR USE | 2017 |
|
RU2778346C2 |
| RECOMBINANT BINDING PROTEINS AND THEIR USE | 2016 |
|
RU2769470C2 |
| HER-2-DIRECTED ANTIGEN-BINDING MOLECULES CONTAINING 4-1BBL | 2019 |
|
RU2815451C2 |
| BISPECIFIC ANTIGEN-BINDING POLYPEPTIDES | 2015 |
|
RU2723940C2 |
| INTRODUCTION OF CONSTRUCTED T CELLS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CANCER | 2017 |
|
RU2757308C2 |
| POLYPEPTIDE COMPRISING ANTIGEN-BINDING DOMAIN AND TRANSPORT SEGMENT | 2018 |
|
RU2815452C2 |
| BISPECIFIC ANTIGEN-BINDING CONSTRUCTS AGAINST HER2 | 2014 |
|
RU2737882C2 |
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
| IMPROVED SINGLE VARIABLE IMMUNOGLOBULIN DOMAINS BINDING TO SERUM ALBUMIN | 2017 |
|
RU2765384C2 |
| ANTIBODIES AGAINST CXCR2 AND THEIR USE | 2019 |
|
RU2807067C2 |
